Thirdly, one, or more, of these behavioural abnormalities of NK1R-/- mice is ameliorated by all four compounds that are licensed for treatment of ADHD: guanfacine (inattentiveness: Pillidge et al., 2014a); atomoxetine (impulsivity (premature responses): Pillidge et al., 2014b); d-amphetamine and methylphenidate (locomotor hyperactivity and perseveration: Pillidge et al., 2016; Yan et al., 2009, 2011). This evidence concerns the gene TACR1 and attention deficit-hyperactivity disorder.